



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

HBXIP (h): 293T Lysate: sc-116745

BACKGROUND

HBXIP (hepatitis B virus X-interacting protein), also known as HBV X-interacting protein or HBX-interacting protein, was originally identified by its ability to form a complex with the C-terminus of hepatitis B virus X (HBX) protein. HBXIP negatively regulates the activity of HBX and alters the replicative life cycle of the virus. HBXIP is an evolutionarily conserved protein. It contains a leucine zipper motif and 2 consensus phosphorylation sites. HBXIP also forms complexes with survivin (an overexpressed protein in most human cancers) and is necessary for allowing survivin to bind and inhibit the activation of pro-caspase-9, suggesting that HBXIP acts as an anti-apoptotic cofactor of survivin. In addition, HBXIP is involved in bipolar spindle formation and regulates centrosome dynamics and cytokinesis in cells, possibly through an interaction with Dynein light chain. The overexpression of HBXIP promotes proliferation in a variety of cells lines.

REFERENCES

1. Melegari, M., Scaglioni, P.P. and Wands, J.R. 1998. Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. *J. Virol.* 72: 1737-1743.
2. Marusawa, H., Matsuzawa, S., Welsh, K., Zou, H., Armstrong, R., Tamm, I. and Reed, J.C. 2003. HBXIP functions as a cofactor of survivin in apoptosis suppression. *EMBO J.* 22: 2729-2740.
3. Capovilla, A. and Arbutnot, P. 2003. Hepatitis B virus X protein does not influence essential steps of nucleotide excision repair effected by human liver extracts. *Biochem. Biophys. Res. Commun.* 312: 806-810.
4. Chandeale, A., Prasad, V., Jagtap, J.C., Shukla, R. and Shastry, P.R. 2004. Upregulation of survivin in G₂/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. *Neoplasia* 6: 29-40.
5. Zangemeister-Wittke, U. and Simon, H.U. 2004. An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy. *Cell Cycle* 3: 1121-1123.
6. Zhang, X., Dong, N., Yin, L., Cai, N., Ma, H., You, J., Zhang, H., Wang, H., He, R. and Ye, L. 2005. Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. *J. Med. Virol.* 77: 374-381.
7. Minczuk, M., Mroczek, S., Pawlak, S.D. and Stepien, P.P. 2005. Human ATP-dependent RNA/DNA helicase hSuv3p interacts with the cofactor of survivin HBXIP. *FEBS J.* 272: 5008-5019.
8. Fujii, R., Zhu, C., Wen, Y., Marusawa, H., Bailly-Maitre, B., Matsuzawa, S., Zhang, H., Kim, Y., Bennett, C.F., Jiang, W. and Reed, J.C. 2006. HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. *Cancer Res.* 66: 9099-9107.
9. Wang, F.Z., Sha, L., Zhang, W.Y., Wu, L.Y., Qiao, L., Li, N., Zhang, X.D. and Ye, L.H. 2007. Involvement of hepatitis B X-interacting protein (HBXIP) in proliferation regulation of cells. *Acta Pharmacol. Sin.* 28: 431-438.

CHROMOSOMAL LOCATION

Genetic locus: LAMTOR5 (human) mapping to 1p13.3.

PRODUCT

HBXIP (h): 293T Lysate represents a lysate of human HBXIP transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

HBXIP (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive HBXIP antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

HBXIP (H-5): sc-373980 is recommended as a positive control antibody for Western Blot analysis of enhanced human HBXIP expression in HBXIP transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



HBXIP (H-5): sc-373980. Western blot analysis of HBXIP expression in non-transfected: sc-117752 (A) and human HBXIP transfected: sc-116745 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.